March 29, 2018 / 8:29 PM / 5 months ago

BRIEF-Ovid Therapeutics Reports Q4 Loss Per Share $0.45

March 29 (Reuters) - Ovid Therapeutics Inc:

* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS

* Q4 LOSS PER SHARE $0.45

* Q4 EARNINGS PER SHARE VIEW $-0.41 — THOMSON REUTERS I/B/E/S

* OVID THERAPEUTICS - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL WITH OV101 FOR TREATMENT OF ADOLESCENTS AND YOUNG ADULTS WITH FRAGILE X SYNDROME IN 2018

* TOPLINE DATA FOR PHASE 1B/2A CLINICAL TRIAL OF TAK-935/OV935 EXPECTED IN SECOND HALF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below